[18F]FES PET/CT in Endocrine Refractory Breast Cancer
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
In this study, positron emission tomography (PET/CT) imaging will be used to evaluate
estrogen receptor (ER) activity in sites of metastatic disease using the investigational
radiotracer [18F]fluoroestradiol (FES).